Dr Reddy's launches Paricalcitol Injection in the US
21 September 2016 | News | By BioSpectrum Bureau
Dr Reddy's launches Paricalcitol Injection in the US
Dr. Reddy's Laboratoriesannounced that it has launched Paricalcitol Injection, USP, in 2 mcg, 5 mcg, 10 mcg, a therapeutic equivalent generic version of Zemplar (paricalcitol) Injection in the United States market approved by the US Food & Drug Administration (USFDA).
The Zemplar brand and generic had US sales of approximately $22.5 million MAT for the most recent twelve months ending in July 2016 according to IMS Health.
Dr. Reddy's Paricalcitol Injection is available in 2 mcg, 5 mcg, and 10 mcg, and is the first ANDA product launched in the US market.
Zemplar is a registered trademark of ABBVIE Inc.
